凯美拉治疗
KYMR
104.78
-3.36
-3.11%
凯美拉治疗
US · KYMR
#1580 按市值排名
上市于 2020
104.78
-3.36
-3.11%
实时 - 追踪5344个代码 - 心跳于403秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量增加了4家。
- 机构持股总比例上升了1.8个百分点。
机构持股
- 机构持股比例
- 112.43% +1.82pp
- 机构数量
- 347 +4
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund69.16%
Hedge Fund30.44%
VC/PE Fund8.67%
Public Company2.19%
Individual/Insider1.18%
Sovereign Wealth Fund0.92%
Private Company0.60%
Government Pension Fund0.26%
Insurance Company0.16%
主要股东 截至 2026-06-30
FMR
14.85% · 12.35M 股
T. Rowe Price Group, Inc.
10.67% · 8.87M 股
Baker Bros. Advisors LP
10.41% · 8.66M 股
Avoro Capital Advisors LLC
8.99% · 7.47M 股
BlackRock
6.66% · 5.54M 股
BVF Partners L.P.
4.66% · 3.87M 股
Wellington Management Group
4.42% · 3.68M 股
Vanguard Capital Management, LLC
4.07% · 3.38M 股
Vanguard Portfolio Management, LLC
3.60% · 2.99M 股
Artal Group S.A.
3.53% · 2.94M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 14次买入 · 36次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Baker Bros. Advisors LP | -- | 10.41% |
| Nello Mainolfi | Chief Executive Officer | 0.80% |
| Bruce Jacobs | Chief Financial Officer | 0.24% |
| Jared Gollob | Chief Medical Officer | 0.09% |
| Brian Adams | Chief Legal Officer | 0.03% |
| Ellen Chiniara | Chief Legal Officer | 0.02% |
| Jeremy Chadwick | Chief Operating Officer | 0.00% |
| Pamela Esposito | Independent Director | 0.00% |
| Noah Goodman | Chief Business Officer | 0.00% |
| Atlas Venture Advisors, Inc. | -- | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-30 | Nello Mainolfi | Chief Executive Officer | Derivative Exercise and Sale | -30,000 | $2.08–116.12 |
| 2026-09-03 | Brian Adams | Chief Legal Officer | Open Market Disposition | -6,371 | $115.55–117.57 |
| 2026-09-01 | Jeremy Chadwick | Chief Operating Officer | Intent to Sell (Form 144) | -10,879 | $119.05 |
| 2026-07-26 | Terence Rooney | Chief Medical Officer | Other Acquisition | +38,000 | -- |
| 2026-07-26 | Terence Rooney | Chief Medical Officer | Other Derivative Acquisition | +76,000 | $110.05 |
| 2026-07-06 | Nello Mainolfi | Chief Executive Officer | Derivative Exercise and Sale | -50,000 | $2.08–119.00 |
| 2026-06-30 | Nello Mainolfi | Chief Executive Officer | Derivative Exercise and Sale | -80,000 | $2.08–116.56 |
| 2026-06-30 | Noah Goodman | Chief Business Officer | Automatic Disposition | -3,389 | $114.29 |
| 2026-06-29 | Bruce Jacobs | Chief Financial Officer | Automatic Disposition | -15,731 | $115.82–117.70 |
| 2026-06-29 | Bruce Jacobs | Chief Financial Officer | Derivative Exercise and Sale | -61,378 | $5.33–115.82 |
| 2026-06-25 | BVF Partners L.P. | -- | Private Disposition | -1,630,658 | $106.50 |
| 2026-06-24 | Noah Goodman | Chief Business Officer | Derivative Exercise and Sale | -5,000 | $21.05–119.00 |
| 2026-06-23 | John Michael Maraganore | Independent Director | Other Derivative Acquisition | +6,068 | $99.87 |
| 2026-06-23 | Felix Baker | Lead Independent Director | Other Derivative Acquisition | +12,136 | $99.87 |
| 2026-06-23 | BVF Partners L.P. | -- | Other Derivative Acquisition | +6,068 | $99.87 |
| 2026-06-23 | Elena Ridloff | Independent Director | Other Derivative Acquisition | +6,068 | $99.87 |
| 2026-06-23 | Bruce Booth | Chairperson | Other Derivative Acquisition | +6,068 | $99.87 |
| 2026-06-23 | Jeffrey Albers | Independent Director | Other Derivative Acquisition | +6,068 | $99.87 |
| 2026-06-23 | Pamela Esposito | Independent Director | Other Derivative Acquisition | +6,068 | $99.87 |
| 2026-06-23 | Victor Sandor | Director | Other Derivative Acquisition | +6,068 | $99.87 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:17 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
凯美拉治疗 讨论区 0 条评论